A Minority Subpopulation of CD133(+) /EGFRvIII(+) /EGFR(-) Cells Acquires Stemness and Contributes to Gefitinib Resistance.

CONCLUSIONS: EGFRvIII contributes to the stemness of cancer stem cells through coexpression with CD133 in GBMs. Furthermore, CD133(+) /EGFRvIII(+) /EGFR(-) cells have the ability to initiate tumor formation and may contribute to gefitinib resistance.
PMID: 23575351 [PubMed - as supplied by publisher]

Source: CNS Neuroscience and Therapeutics - April 10, 2013 Category: Neuroscience Authors: Liu XJ, Wu WT, Wu WH, Yin F, Ma SH, Qin JZ, Liu XX, Liu YN, Zhang XY, Li P, Han S, Liu KY, Zhang JM, He QH, Shen L Tags: CNS Neurosci Ther Source Type: research